Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 6626 - 6650 of 7701 in total
Lisofylline has been investigated for the treatment of Type 1 Diabetes Mellitus.
Investigational
Matched Iupac: … 1-[(5R)-5-hydroxyhexyl]-3,7-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione …
Dtp348 has been used in trials studying the treatment of Solid Tumors and Head and Neck Neoplasms.
Investigational
Matched Iupac: … N-[2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl]aminosulfonamide …
AKN-028 has been used in trials studying the treatment of Acute Myeloid Leukemia.
Investigational
Matched Iupac: … N2-(1H-indol-5-yl)-6-(pyridin-4-yl)pyrazine-2,3-diamine …
Ripasudil, as hydrochloride hydrate (K-115), is a specifc Rho-associated coiled-coil containing protein kinase (ROCK) inhibitor used for the treatment of glaucoma and ocular hypertension. It was first approved for treatment in Japan in September 2014. This medication is available in the form of a 0.4% eye drop solution under the...
Experimental
Matched Iupac: … 4-fluoro-5-{[(2S)-2-methyl-1,4-diazepan-1-yl]sulfonyl}isoquinoline …
Experimental
Matched Iupac: … 5-ethoxy-2-{[2-(morpholin-4-yl)ethyl]sulfanyl}-1H-1,3-benzodiazole …
A natural product found in Cannabis sativa and Helichrysum species.
Experimental
Matched Iupac: … 2-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-5-pentylbenzene-1,3-diol …
SAR405838 has been used in trials studying the treatment of Neoplasm Malignant.
Investigational
Matched Iupac: … (2'S,3R,4'S,5'R)-6-chloro-4'-(3-chloro-2-fluorophenyl)-2'-(2,2-dimethylpropyl)-2-oxo-N-[(1r,4r)-4-hydroxycyclohexyl ... ]-1,2-dihydrospiro[indole-3,3'-pyrrolidine]-5'-carboxamide …
Bitolterol mesylate was used to treat bronchospasms in asthma and COPD. It is a beta-2-adrenergic receptor agonist. Bitolterol was withdrawn from the market by Elan Pharmaceuticals in 2001.
Withdrawn
Matched Iupac: … 5-[2-(tert-butylamino)-1-hydroxyethyl]-2-(4-methylbenzoyloxy)phenyl 4-methylbenzoate …
Experimental
Matched Iupac: … (1S,3R,4R,5S)-1,3,4-trihydroxy-5-(phosphonomethyl)cyclohexane-1-carboxylic acid …
Experimental
Matched Iupac: … (2R,3S,4R,5R)-5-{[(1S)-1-hydroxyethyl]amino}hexane-1,2,3,4,6-pentol …
Experimental
Matched Iupac: … 3-[5-methoxy-1-(4-methoxybenzenesulfonyl)-1H-indol-3-yl]propanoic acid …
Nolatrexed is under investigation in clinical trial NCT00012324 (Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With Recurrent or Unresectable Liver Cancer).
Investigational
Matched Iupac: … 2-amino-6-methyl-5-(pyridin-4-ylsulfanyl)-3,4-dihydroquinazolin-4-one …
Experimental
Matched Iupac: … 6-chloro-2-cyclohexyl-3-oxo-2,3-dihydro-1H-isoindole-5-sulfonamide …
Prevents renal injury after warm & cold ischemia.
Experimental
Matched Iupac: … 5-[methyl(2-phenylethyl)amino]-2-phenyl-2-(propan-2-yl)pentanenitrile …
Vercirnon is a novel, orally active anti-inflammatory agent that targets a chemokine receptor protein implicated in both Crohn's disease and ulcerative colitis, the two principal forms of IBD. It is under investigation in clinical trial NCT01611805 (Japanese Phase I of GSK1605786).
Investigational
Matched Iupac: … 4-[2-(4-tert-butylbenzenesulfonamido)-5-chlorobenzoyl]pyridin-1-ium-1-olate …
Investigational
Matched Iupac: … chromium(3+) tris((2S)-2-amino-3-(1H-imidazol-5-yl)propanoate) …
Experimental
Matched Iupac: … (2S)-2-amino-N-[(1S)-3-amino-1-carbamoylpropyl]-5-(N'-nitrocarbamimidamido)pentanamide …
Tolrestat (INN) (AY-27773) is an aldose reductase inhibitor which was approved for the control of certain diabetic complications. While it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval. It was sold under the tradename...
Withdrawn
Matched Iupac: … 2-{1-[6-methoxy-5-(trifluoromethyl)naphthalen-1-yl]-N-methylmethanethioamido}acetic acid …
Experimental
Matched Iupac: … 2-amino-5-(aminomethyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one …
Experimental
Matched Iupac: … (2S,3R,4R,5S,6R)-6-(hydroxymethyl)-2-methoxy-5-sulfanyloxane-3,4-diol …
Experimental
Matched Iupac: … N-[3-benzyl-5-(4-hydroxyphenyl)pyrazin-2-yl]-2-(4-hydroxyphenyl)acetamide …
MK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders. It targets G protein-coupled receptor, or GPCR, that have the potential to regulate plasma lipid profiles, including HDL, or the good cholesterol, similar to the therapeutic action of niacin.
Investigational
Matched Iupac: … 5-{1H,4H,5H,6H-cyclopenta[c]pyrazol-3-yl}-2H-1,2,3,4-tetrazole …
MDI-P has demonstrated potent anti-HIV activity. MDI-P has been shown to be effective in killing HIV in cell culture. HIV is the virus that causes acquired immune deficiency syndrome (AIDS). MDI-P is also a potential therapeutic agent for the treatment of the symptoms of cystic fibrosis ("CF").
Investigational
Matched Iupac: … [1-(2H-1,3-benzodioxol-5-yl)propan-2-yl](propan-2-yl)amine …
Investigational
Matched Iupac: … (5R)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine …
UK-396,082 has been used in trials studying the basic science of Safety, Phase 1, Toleration, Multiple Dose, and Pharmacokinetic.
Investigational
Matched Iupac: … (2S)-5-amino-2-[(1-propyl-1H-imidazol-4-yl)methyl]pentanoic acid …
Displaying drugs 6626 - 6650 of 7701 in total